Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823450 | 1.00 | POLB (0.40) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 | |
| SCHEMBL2843889 | 0.87 | POLB (0.37) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 | |
| SCHEMBL6760115 | 0.87 | POLB (0.37) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 | |
| SCHEMBL8238400 | 0.87 | POLB (0.37) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 | |
| SCHEMBL2843887 | 0.87 | POLB (0.37) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 | |
| SCHEMBL14020643 | 0.86 | POLB (0.38) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 | |
| SCHEMBL6828084 | 0.79 | HSD17B10 (0.32) | — | |
| SCHEMBL16628788 | 0.79 | POLB (0.40) | POLBALDH1A1MAPTSMN1; SMN2CYP2C9 | |
| SCHEMBL16628787 | 0.79 | POLB (0.40) | POLBALDH1A1MAPTSMN1; SMN2CYP2C9 | |
| SCHEMBL12730845 | 0.78 | SMN1; SMN2 (0.37) | POLBALDH1A1MAPTSMN1; SMN2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183277-B2 | Inhibitors of HCV replication of formula (I)** Image-1whereinW is a heterocycle of formula** Image-2and the remaining variables are as defined in the specification. | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, EIF2AK2 | POLB 763/4885ALDH1A1 2403/4885MAPT 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.